It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
XRAY’s FA Score shows that 1 FA rating(s) are green whileZBH’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
XRAY’s TA Score shows that 5 TA indicator(s) are bullish while ZBH’s TA Score has 6 bullish TA indicator(s).
XRAY (@Pharmaceuticals: Other) experienced а +3.27% price change this week, while ZBH (@Medical/Nursing Services) price change was +2.62% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.75%. For the same industry, the average monthly price growth was +0.04%, and the average quarterly price growth was +13.98%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.03%. For the same industry, the average monthly price growth was +3.31%, and the average quarterly price growth was +18.95%.
XRAY is expected to report earnings on Nov 06, 2025.
ZBH is expected to report earnings on Nov 05, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+1.03% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
XRAY | ZBH | XRAY / ZBH | |
Capitalization | 2.52B | 19.8B | 13% |
EBITDA | -689M | 2.28B | -30% |
Gain YTD | -31.254 | -4.725 | 662% |
P/E Ratio | N/A | 24.37 | - |
Revenue | 3.67B | 7.83B | 47% |
Total Cash | 1.27B | N/A | - |
Total Debt | 2.49B | 7.57B | 33% |
XRAY | ZBH | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 64 | 56 | |
P/E GROWTH RATING 1..100 | 86 | 27 | |
SEASONALITY SCORE 1..100 | 37 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (4) in the Medical Specialties industry is in the same range as ZBH (20). This means that XRAY’s stock grew similarly to ZBH’s over the last 12 months.
XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ZBH (100). This means that XRAY’s stock grew similarly to ZBH’s over the last 12 months.
XRAY's SMR Rating (100) in the Medical Specialties industry is in the same range as ZBH (100). This means that XRAY’s stock grew similarly to ZBH’s over the last 12 months.
ZBH's Price Growth Rating (56) in the Medical Specialties industry is in the same range as XRAY (64). This means that ZBH’s stock grew similarly to XRAY’s over the last 12 months.
ZBH's P/E Growth Rating (27) in the Medical Specialties industry is somewhat better than the same rating for XRAY (86). This means that ZBH’s stock grew somewhat faster than XRAY’s over the last 12 months.
XRAY | ZBH | |
---|---|---|
RSI ODDS (%) | 2 days ago62% | 2 days ago47% |
Stochastic ODDS (%) | 2 days ago56% | 2 days ago61% |
Momentum ODDS (%) | 2 days ago73% | 2 days ago58% |
MACD ODDS (%) | 2 days ago56% | 2 days ago56% |
TrendWeek ODDS (%) | 2 days ago59% | 2 days ago58% |
TrendMonth ODDS (%) | 2 days ago74% | 2 days ago58% |
Advances ODDS (%) | 3 days ago57% | 2 days ago62% |
Declines ODDS (%) | 8 days ago72% | 8 days ago56% |
BollingerBands ODDS (%) | 2 days ago54% | 2 days ago66% |
Aroon ODDS (%) | 2 days ago78% | 2 days ago54% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
BTAL | 15.42 | 0.06 | +0.39% |
AGF U.S. Market Neutral Anti-Beta | |||
IBDW | 21.34 | 0.07 | +0.33% |
iShares iBonds Dec 2031 Term Corp ETF | |||
BDVG | 12.54 | -0.09 | -0.71% |
iMGP Berkshire Dividend Growth ETF | |||
AFMC | 33.49 | -0.34 | -1.02% |
First Trust Active Factor Mid Cap ETF | |||
BITW | 73.09 | -1.78 | -2.37% |
Bitwise 10 Crypto Index Fund |
A.I.dvisor indicates that over the last year, ZBH has been loosely correlated with IART. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBH jumps, then IART could also see price increases.
Ticker / NAME | Correlation To ZBH | 1D Price Change % | ||
---|---|---|---|---|
ZBH | 100% | +0.54% | ||
IART - ZBH | 53% Loosely correlated | +2.67% | ||
ENOV - ZBH | 48% Loosely correlated | N/A | ||
ITGR - ZBH | 44% Loosely correlated | -0.66% | ||
HOLX - ZBH | 43% Loosely correlated | +2.24% | ||
SYK - ZBH | 43% Loosely correlated | -0.14% | ||
More |